GLP-1 drugs such as Ozempic and Wegovy are providing new challenges for diet brands and gyms, who have seen a surge in demand ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the ...

Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.